
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is well positioned to continue its upward revenue trend with a strong portfolio of OviTex products, demonstrated by impressive unit sales growth in the quarter and a solid gross margin of 65.9%. However, as reimbursement for certain healthcare procedures remains a key driver for TELA Bio's success, changes in reimbursement rates, especially in the evolving US healthcare landscape, could negatively impact the company's growth potential. Internationally, government control of pricing could also limit utilization of the company's products.
Bears say
TELA Bio is facing significant challenges that are impacting its financial performance and outlook, including an underwhelming first quarter and lowered full-year guidance for 2026. The company has had to navigate through sales force restructuring, strategic challenges, and lower than expected sales growth, which has led to a significant decrease in its stock price. While the company has a strong product portfolio, its concentrated focus on surgical mesh products and heavy reliance on regulatory approvals makes it vulnerable to potential disruptions and delays in the future. With these ongoing challenges, it is uncertain if TELA Bio will be able to successfully meet investor expectations and generate sustained growth.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares